CL2021001829A1 - Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa - Google Patents

Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa

Info

Publication number
CL2021001829A1
CL2021001829A1 CL2021001829A CL2021001829A CL2021001829A1 CL 2021001829 A1 CL2021001829 A1 CL 2021001829A1 CL 2021001829 A CL2021001829 A CL 2021001829A CL 2021001829 A CL2021001829 A CL 2021001829A CL 2021001829 A1 CL2021001829 A1 CL 2021001829A1
Authority
CL
Chile
Prior art keywords
antibodies
treatment
hidradenitis suppurativa
suppurativa
hidradenitis
Prior art date
Application number
CL2021001829A
Other languages
English (en)
Inventor
Pascal Espie
James Rush
Christian Loesche
Lukas Roth
Grazyna Wieczoreck
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021001829A1 publication Critical patent/CL2021001829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La divulgación se refiere a métodos, regímenes de tratamiento, usos, equipos y terapias para tratar la hidradenitis supurativa, mediante el empleo de antagonistas de CD40, tales como anticuerpos anti-CD40.
CL2021001829A 2019-01-11 2021-07-08 Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa CL2021001829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19151461 2019-01-11

Publications (1)

Publication Number Publication Date
CL2021001829A1 true CL2021001829A1 (es) 2022-04-22

Family

ID=65019425

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001829A CL2021001829A1 (es) 2019-01-11 2021-07-08 Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa

Country Status (13)

Country Link
US (1) US20220098315A1 (es)
EP (1) EP3908310A1 (es)
JP (2) JP2021506953A (es)
KR (1) KR20210114964A (es)
CN (1) CN113271964A (es)
AU (1) AU2020205839A1 (es)
BR (1) BR112021013174A2 (es)
CA (1) CA3125886A1 (es)
CL (1) CL2021001829A1 (es)
IL (1) IL284338A (es)
MX (1) MX2021008305A (es)
TW (1) TW202033558A (es)
WO (1) WO2020144605A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4213939A1 (en) * 2020-09-21 2023-07-26 Boehringer Ingelheim International GmbH Use of anti-cd40 antibodies for treatment of inflammatory conditions
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
SI3178851T1 (sl) 2010-03-31 2020-09-30 Boehringer Inhelheim International Gmbh Anti-CD40 protitelesa
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP3320902B1 (en) * 2011-03-07 2021-02-17 Amgen (Europe) GmbH Methods for treating diseases using isoindoline compounds
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
SI3303395T1 (sl) * 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
EP3716982A4 (en) * 2017-12-01 2021-08-11 AbbVie Inc. ANTI-CD40 ANTIBODY INGREDIENT CONJUGATES

Also Published As

Publication number Publication date
WO2020144605A1 (en) 2020-07-16
KR20210114964A (ko) 2021-09-24
JP2021506953A (ja) 2021-02-22
MX2021008305A (es) 2021-08-24
JP2021181439A (ja) 2021-11-25
CA3125886A1 (en) 2020-07-16
EP3908310A1 (en) 2021-11-17
CN113271964A (zh) 2021-08-17
TW202033558A (zh) 2020-09-16
BR112021013174A2 (pt) 2021-11-03
AU2020205839A1 (en) 2021-06-03
US20220098315A1 (en) 2022-03-31
IL284338A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
BR112017007003A2 (pt) método para modulação de atividade de células imunes induzidas por car
CL2019001553A1 (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112017023576A2 (pt) Método para tratar uma disfunção proliferativa de células b
CO2019012473A2 (es) Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
CO2017008804A2 (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
AU2017241807A1 (en) Medium, methods, cells and secreted factors for stem cell culture and therapy
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
AR091220A1 (es) Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa
UY35406A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
TW201713333A (en) Methods of treating a neurodegenerative disease
BR112016024630A2 (pt) composição tópica, uso de uma composição tópica e aplicador
SG10201804034QA (en) Methods for treating hypotension